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Asymptomatic left ventricular systolic dysfunction (ALVSD), or stage
B heart failure (HF), is associatedwith increased cardiovascular (CV) and
all-causemortality, and nonfatal CV events [1,2]. ALVSD is distinctlymore
common among subjects with stage A HF [3].
ALVSD remains commonly underdiagnosed, particularly in primary
care, where diagnostic facilities are limited. Routine echocardiography,
the diagnostic gold standard for ALVSD, is not the screening strategy of
choice due to lack of accessibility and cost. Alternative approaches using
risk scores and biomarkers have beenproposed. The FraminghamHF risk
score (FHFRS) score [4] is a gender-specific risk stratification tool to
identify patients at high risk of developing HF within 4 years. Natriuretic
peptides (NP) have been evaluated as screening tools for
further evaluation in several studies [5–7] and showed prognostic
value in stage A/B patients [8].
DAVID-Berg was a prospective cohort study carried out at three
primary care group practices in the Northern Italy city of Bergamo to
analyse the relative merit of the FHFRS and N-terminal pro-brain
natriuretic peptide (NT-proBNP) to screen for ALVSD from a primary
care perspective. Each primary care physician reviewed the clinical
records of all patients aged N55 and b80 years. Patients with known or
suspectedHFrequiring diagnostic validation or severe comorbiditywith
reduced life expectancy were excluded.
We recruited for screening subjects considered at high risk of ALVSD
because of history of any of ischemic heart disease, cerebrovascular or
peripheral vessel disease; diabetes; hypertension with evidence of
target organ damage (retinopathy; atrial fibrillation, glomerular
filtration rate b60 ml/min). Patients gave their written informed
consent to participate in study which was approved by the Ethics
Committee of the Local Health Authority.
Patients attended the primary care offices to perform measurement
of height, weight, and blood pressure, standard 12-lead electrocardio-
gram (ECG), blood sampling for NT-proBNP, and a Color Doppler
echocardiogram, according to American Society of Echocardiography
guidelines. Left ventricular ejection fraction (LVEF) was calculated with
biplane Simpson rule. ALVSD was defined as LVEF b 50%. LV
hypertrophy on ECG was blindly coded by Minnesota Code. We
calculated the FHFRS using the simplified algorithm [4]. NT-proBNP
was measured with competitive enzyme immunoassay (Cardiac
Reader Roche Diagnostic). We considered as reference abnormal cut-
off the95th percentile of the age- andgender-specific distributionofNT-
proBNP in normal blood-donors, reported by the manufacturer.
The association between AVLSD and the FHFRS, NT-proBNP, and their
combination were assessed by logistic regression analysis, model
calibration by Hosmer–Lemeshow goodness-of fit test and predictive
performance by the C statistic. The areas under the ROC curve (AUC)
with their 95% confidence interval were compared by the method of De
Long et al.
Among a total population of 13,625, GPs reviewed the clinical
records of 4047 subjects (50.5% women) aged N55 and b80 years. Of
these, 623 (15.4%) patients identified as being at high CV risk were
screened. ALVSD was found in 33 (5.3%) patients (Table 1). Both FHFRS
and NT-proBNP levels were significantly higher in patients with mild
ALVSD than in subjects with normal LVEF. Median NT-proBNP were
significantly more elevated in higher FHFRS tertiles in both genders, but
concentrations overlapped widely (Fig. 1).
By logistic regression, mild ALVSD was significantly associated to
stand alone FHFRS (AUC 0.63, 95% CI: 0.53–0.73), stand alone NT-proBNP
levels (AUC 0.74, 95% CI: 0.70–0.77, p = 0.011) and their
combination (AUC 0.76, 95% CI: 0.67–0.84, p=0.04).
TheHosmer–Lemeshowdemonstrated overall good calibration for all
models.
Patient with an abnormal NT-proBNP had a six-fold increase in the
risk of mild ALVSD (odds ratio of 6.12 (95% CI 2.85–13.1). The negative
predictive value for ALVSD of a FHFRS ≥15 and of an abnormal NT-
proBNP were 96% and 97.7%, respectively.
We found that in an elderly cohort of patients at high CV risk in
primary care NT-proBNP levels are better predictors of ALVSD than
FHFRS. Since NP offer practical advantages over the ECG in primary care,
it may be advocated as first test for screening in these patients.
The optimal strategy to identify ALVSD in a general population is still
uncertain. So far direct comparison of HF risk scores to NP was only
investigated by Gupta et al. [9]. These authors compared the diagnostic
utility of the Health ABCHF risk score, the FHFRS andNP plasma levels in
identifying prevalent AHA/ACC stage B HF, in a young (mean age
48 years) multiethnic cohort, in whom ALVSD prevalence was 3%.
Among white participants, the Health ABC HF risk score and both NP
performed poorly (C-statistic 0.62, 0.63, 0.60, respectively) and the
FHFRS was superior to both with moderate discrimination (C-statistic
0.71).
A possible explanation for the modest predictive performance of the
FHFRS, confirmed by our findings, is that in the Framingham cohort
incident HF diagnosis was based on signs and symptoms and did not
include an objective assessment of LV function.
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ECG as stand-alone test has been previously shown to have a high
negative predictive value for severe or moderate ALVSD, only when
interpreted by a cardiologist. Since NP offer distinct practical advantages
in the primary care setting with respect to the ECG, NP testing could be
the best strategy to “rule out” ALVSD in primary care in the young
elderly. Among “oldest old” (N80 years) subjects, prevalence of cardiac
dysfunction and HF symptoms increases, the opportunities for
prevention shrink and NP and ECG may add little predictive value to
a clinical model.
We used the age and gender-specific 95th percentile concentrations
for NT-proBNP, as provided by themanufacturer and commonly reported
in laboratory test results, rather than testing a particular cut off. While
this method may be less intuitive than a single value for all, it seems to
make more sense given the high variance of NP levels according to age
and sex.
In an elderly primary care population at high CV risk,measurement of
NT-proBNP seems superior to the FHFRS in predicting ALVSD. Because of
its practical advantages, NT-proBNP might be routinely used in this
setting as accurate tool to identify patients to be referred for further
investigation.
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Table 1
Baseline characteristics of the study cohort.
All cases No ALVSD Mild ALVSD p*
(n= 619) (n= 586) (n= 33) Value
Male gender 347 (56%) 322 (55%) 25 (76%) 0.019
Smoking 78 (13%) 75 (13%) 3 (9%) 0.787
History of Hypertension (n= 581) 547 (89%) 522 (90%) 25 (76%) 0.018
Type 2 Diabetes (n= 582) 196 (33%) 186 (34%) 10 (31%) 0.849
Chronic kidney dysfunction (n= 587) 111 (18.9%) 107(19.3%) 4 (12.5%) 0.486
Ischemic heart disease 205 (33%) 184 (31%) 21 (64%) b0.001
Valvular heart disease 17 (3%) 13 (2%) 4 (12%) 0.010
Myocardial infarction (n= 544) 111 (20%) 93 (18%) 18 (58%) b0.001
Cerebrovascular disease (any) (n= 587) 129 (21%) 123 (21%) 6 (18%) 0.828
Peripheral Vascular Disease (n= 529) 49 (9%) 45 (9%) 4 (14%) 0.316
Left ventricular hypertrophy on ECG 31 (5%) 27 (5%) 4 (12%) 0.076
Atrial fibrillation 23 (4%) 19 (3%) 4 (12%) 0.026
Framingham Heart Failure Risk Score 11 [9–16] 11 [9–15] 14 [10–17] 0.013
Age, years 70 [64–75] 70 [64–75] 67 [61–73] 0.154
Systolic blood pressure, mmHg 151 [134–166] 152 [134–166] 142 [124–166] 0.113
Diastolic blood pressure, mmHg 84 [76–91] 84 [77–91] 82 [70–92] 0.257
Heart rate, bpm 69 [60–78] 69 [60–78] 66 [59–71] 0.160
Body mass index, kg/m2 28 [25–32] 28 [25–32] 28 [26–30] 0.619
Waist circumference, cm 99 [92–107] 99 [92–107] 98 [93–106] 0.580
Glucose, mg/dl 105 [95–128] 104 [95–128] 110 [97–124] 0.350
Glomerular filtration rate, ml/min 77 [64–92] 77 [64–92] 77 [64–88] 0.773
Total cholesterol, mg/dl 202 [174–228] 202 [175–228] 201 [169–214] 0.294
HDL cholesterol, mg/dl 51 [44–62] 51 [44–61] 48 [37–62] 0.323
LDL cholesterol, mg/dl 120 [95–145] 120 [96–145] 113 [85–133] 0.172
Triglycerides, mg/dl 124 [93–165] 124 [92–163] 141 [106–191] 0.073
NT-proBNP, pg/ml 180 [88–355] 170 [87–328] 569 [305–1314] b0.001
Data are expressed as n (%) or median [quartile 1-quartile 3]. * Student's t-test for continuous variables, chi-square test or Fisher's exact test for categorical variables and Mann–
Whitney test for skewed variables.
ALVSD: Asymptomatic left ventricular systolic dysfunction; LVH: left ventricular hypertrophy; NT-proBNP: N-terminal pro-brain natriuretic peptide.
Fig. 1. Box plot of NT-proBNP distribution (median, interquartile range and 95th
percentile) according to gender and tertiles of the Framingham Heart Failure Risk Score
(FHFRS). p Values are by Kruskall–Wallis test with Bonferroni correction.
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To the Editor:
In their comment to our recent paper entitled “Stressed Brain,
Diseases Heart: A review on the pathophysiologic mechanisms of
neurocardiology.” [1], Dominguez-Rodriguez and Abreu-Gonzalez [2]
emphasize the relevance of circadian rhythm in cardiovascular diseases
and propose the suprachiasmatic nucleus and melatonin as key
mediators in its pathophysiology. We found this a very interesting
observation. The incidence of acute myocardial infarction [3] and its
extension [4] displays a circadian pattern usually peaking in early
morning. Whether this is a consequence of the oscillating levels of
circulating hormones or from a direct action of central mechanisms on
the heart and vessels themselves is still a matter of dispute.
In addition to melatonin, also cortisol has been implicated in the
circadian variation of cardiovascular diseases. Cortisol is produced by
the adrenal glands following a circadian pattern with the zenith 1 h
before awakening. Interestingly, there is evidence that more relevant
than the levels of cortisol at peaks, is the sustained elevation of
cortisol (measured in the hair and reflecting the accumulated
circulating levels in the previous three months), that has been
associated with a significant risk of cardiovascular events [5]. In fact,
in a cohort of 4047 patients from the Whitehall II study, Kumari and
colleagues showed that flatter slopes in cortisol decline across the
day, but not peak morning cortisol levels, were associated with
increased risk of all-cause and cardiovascularmortality in a follow-up
period of 6 years [6]. In addition, in a recent pilot study, we observed
that higher blood cortisol levels at admission to a cardiac care unit
were related with a worst outcome during the in-hospital stay
regarding left ventricular function and Killip class (Pereira et al.,
Poster Presentation, Heart Failure 2013). These observations suggest
that higher levels of cortisol are associated with worst cardiovascular
outcome at the long-term, but fail to demonstrate a direct association
betweenpeak levels of cortisol and acute events; this brings to scene the
possible role of other mediators in the circadian variation of cardiovas-
cular diseases, which may well include melatonin.
Finally it is interesting to note the relation between stress and
the disruption of global circadianism. Chronic stress disturbs the
normal circadian rhythm, altering the normal variation of both
cortisol [7] and melatonin [8], and directly impairing pineal
sympathetic inputs [8], which may well contribute to the increased
risk of cardiovascular diseases in patients under chronic psycholo-
gical stress. The effects of chronic stress in the suprachiasmatic
nucleus need to be investigated in greater detail. Highlighting these
poorly studied aspects and relating what may seem disperse
evidence, will certainly pave the way of neurocardiology and
further studies, both at basic and clinical levels, and will be critical
to clarify the role of circadian clock regulators in the incidence and
natural history of cardiovascular events.
The authors of this manuscript have certified that they comply with
the Principles of Ethical Publishing in the International Journal of
Cardiology.
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